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Abstract
Background: The use of anti-malarial drug combinations with artemisinin or with one of its
derivatives is now widely recommended to overcome drug resistance in falciparum as well as vivax
malaria. The fixed oral dose artemisinin-naphthoquine combination (ANQ, ARCO™) is a newer
artemisinin-based combination (ACT) therapy undergoing clinical assessment. A study was
undertaken to assess the safety, efficacy and tolerability of ANQ combination in areas of multi-drug
resistance to generate preliminary baseline data in adult population of Papua New Guinea.
Methods: The clinical assessment was an open-labeled, two-arm, randomized study comparing
ANQ combination as a single dose regimen and three days regimen (10 mg/kg/day) of chloroquine
plus single dose sulphadoxine-pyrimethamine (CQ+SP) for the treatment of uncomplicated
falciparum malaria with 28 days follow-up in an adult population. The primary outcome measures
for efficacy were day 1, 2, 3 7, 14 and 28-day cure rates. Secondary outcomes included parasite
clearance time, fever clearance time, and gametocyte carriage. The main outcome measures for
safety were incidences of post-treatment clinical and laboratory adverse events.
Results:  Between June 2005 and July 2006, 130 patients with confirmed uncomplicated P.
falciparum were randomly assigned to receive ANQ and CQ+SP, only 100 patients (51 in ANQ
group and 49 in CQ+SP group) were evaluated for clinical and parasitological outcomes. All the
patients treated with ANQ and CQ+SP showed adequate clinical and parasitological response with
28 days follow-up. The cure rate for ANQ on day 1, 2, 3, 7, 14, and 28 was 47%, 86%, 92%, 94%,
94% and 94%, respectively. Recrudescence account for 6%; all were cleared on day 21. For CQ+SP
treated group the cure rates were 24%, 67%, 82%, 82%, 84% and 88%, respectively. Recrudescence
accounted for 10%; all were cleared on day 28 except for one patient. Both regimens were well
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tolerated with no serious adverse events. The proportion of gametocyte carriers was higher in
CQ+SP treated group than ANQ treatment (41% versus 12%; p < 0.05).
Conclusion: While these data are not themselves sufficient, it strongly suggests that the ANQ
combination as a single dose administration is safe and effective for the treatment of uncomplicated
P. falciparum malaria in the adult population of Papua New Guinea and deserves further clinical
evaluation.
Introduction
In Papua New Guinea (PNG), malaria is one of the lead-
ing causes of morbidity and mortality, particularly among
children under five years of age. The most predominant of
the four species are Plasmodium falciparum (P. falciparum)
and Plasmodium vivax (P. vivax) [1,2]. The vast majority of
malaria-related deaths are due to P. falciparum infections
but equally important are the P. vivax infections which
cause severe febrile illnesses but are rarely fatal. The trans-
mission of malaria has increased over the past decade
[2,3], partly as result of lack of funds for malaria control
programs, massive population movement from non-
malaria areas to malaria endemic areas and vise versa for
employment opportunities, climate changes, and wide-
spread multi-drug resistance to currently available anti-
malarials [4-6].
The 4-aminoquinolines (chloroquine [CQ] for adults/
amodiaquine for children) have been used as the first-line
anti-malarial drugs for malaria treatment for many years.
However, the therapeutic efficacy of the 4-aminoquino-
lines, particularly of chloroquine, has declined over the
years [5,6] since the mid-70s [7]. In an effort to sustain the
therapeutic efficacy, the PNG National Department of
Health added sulphadoxine-pyrimethamine (SP) to the 4-
aminoquinolines [8]. Despite the effort clinical resistance
to the CQ+SP combination emerged soon after its intro-
duction [9]. The clinical observations are support by
molecular studies where many of the clinical isolates of P.
falciparum carry multi-drug resistant genes [10-12], which
meant that new anti-malarial combinations have to be
sought. The artemisinin and/or its derivatives have widely
been advocated for combating multi-drug resistance [13-
15]. Although artemisinin-based combination therapies
(ACTs) are known to be effective anti-malarials [16,17],
PNG is yet to introduce ACTs into its national malaria
treatment policy. In an effort to effect policy change from
CQ+ SP, which is the current first-line treatment, to ACT,
to replace current first-line treatment, several different
combinations have recently been evaluated in PNG [18].
The ANQ combination is one of the new generations of
fixed-dose ACTs, which was evaluated in this study. The
combination tablet was initially developed by the Acad-
emy of Military Medical Sciences (AMMS), Beijing, China
and is currently administered as a single-dose regimen.
Although clinical experiences and clinical data are very
limited, available pre-clinical and clinical data claim that
ANQ is safe and effective in a single dose administration
[19,20]. The results of this study show ANQ to be compar-
atively safe, tolerable and efficacious.
Patients and methods
Study site and patient selection
Three hospitals were selected for the study; two in Port
Moresby, southern region, and Madang in the northern
region (Figure 1). Moderate to high malaria transmission
with the predominance of P. falciparum and P. vivax infec-
tions with high prevalence of multi-drug resistant P. falci-
parum  are experienced in both regions [4-6,21]. The
patients for the study were selected on the following inclu-
sion criteria: (i) positive thick blood smear of pure P. fal-
ciparum infection (ii) age 14 years and over, (iii) agreed to
28-day follow-up, (iv) parasitaemia of 500 parasites/μL
and over (later it was changed to ≥ 250 parasites/μL due
to slow in recruiting patients), and (v) signed informed
consent form. The exclusion criteria were: (i) danger signs
of severe malaria, (ii) pregnancy, (iii) history of allergy to
study drugs, (iv) taken anti-malarial drugs in the last seven
days, and (v) medical history or concurrent systemic med-
ical conditions. The exiting criteria from the study were:
(i) completion of the 28-day period, (ii) identification of
mixed species infection in the course of study, (iii) devel-
opment of serious drug related toxicity, (iv) progression
of signs and symptoms indicative of impending severity of
malaria, and (v) developed non-malaria infections during
the course of the study. The study was designed as an
open-label, two-arm, randomized study comparing a sin-
gle dose ANQ (ARCO™ 125/50, Kunming Pharmaceuti-
cals, Kunming (KPC), China) with three days CQ and
single dose SP (CQ+SP), the current first line treatment for
malaria in PNG. The Research Committee of the School of
Medicine and Health Sciences, University of Papua New
Guinea, and the Medical Research Advisory Committee
(MRAC) of the PNG National Department of Health
(MRAC #:1529) gave the ethical approval for the study.
Study and laboratory procedures
The trial patients were admitted to the hospital for the first
three days (72-hrs). On admission (day 0), a medical his-
tory and a full physical examination were performed on
all patients. Venous blood (~10 ml) was collected for bio-
chemistry, haematology, and renal function tests. BloodMalaria Journal 2009, 8:196 http://www.malariajournal.com/content/8/1/196
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smears for parasite microscopy were done on 0, 8, 16, 24,
32, 40, 48, 60 and 72 hrs before patients were discharged
from hospital. Thereafter patients were asked to return to
the hospital on days 7, 14, 21, and 28. On each visit a full
physical examination, blood smears and collection of
venous blood (5 ml) were done for each patient; blood
smears for parasite microscopy and venous blood for bio-
chemistry, haematology, and renal function tests. In addi-
tion, a questionnaire on adverse events was completed for
each patient. Any patients complaining of fever or symp-
toms consistent with malaria, a blood smear was taken
and microscopically examined during the follow-up
period.
The malaria parasite counts were determined on 10%
Giemsa stained thick blood smears under high power
magnification (10 × 100). Parasitaemia was measured by
counting a number of asexual parasites against 200 white
blood cells (WBC). However, where parasites decreased
following treatment such that parasites may fall below 10
parasites per 200 white blood cells, count was done
against 500 WBC. The parasitaemia (parasites/μl of
blood) was calculated based on the number of asexual
forms seen in 200 WBC multiplied by 8000 [22]. The
blood smears were pronounced negative after having
examined 100 fields of a thick smear. Presence or absence
of gametocytes was noted per 500 WBC with Giemsa
stained thick smears. The blood smears were read by two
laboratory technicians experienced (15+ years) in malaria
diagnosis.
Drug regimens
The trial patients were randomized to either of the two
treatments using a table of random numbers adopted
from Geigy Scientific Tables [23]. Patients allocated to ANQ
received a total of 1000 mg of artemisinin and 400 mg
The map of Papua New Guinea showing the locations of the study in the two regions Figure 1
The map of Papua New Guinea showing the locations of the study in the two regions.Malaria Journal 2009, 8:196 http://www.malariajournal.com/content/8/1/196
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naphthoquine in 8 tablets as a single dose dispensed with
water. Each tablet contained 125 mg of artemisinin and
50 mg of naphthoquine. Patient allocated to CQ+SP
group received CQ and SP separately. Each tablet of CQ
contained 150 mg and the number of tablets given accord-
ing to body weight; dispensed as 10 mg/kg daily for three
days with water. Each tablet of SP contained sulphadoxine
500 mg and pyrimethamine 25 mg. SP was dispensed as a
fixed dose combination tablet according to weight based
on 25 mg/kg of sulphadoxine component. The maximum
dosage for patients weighing more than 50 kg was four
tablets per dose and patients weighing 50 kg or less
received three tablets per dose. SP was given on the first
day of treatment along with first dose of CQ. All the drugs
were administered under close supervision of the hospital
staff. None of the patients vomited within 20 minutes of
taking medication, which could have necessitated repeat-
ing the same drug dosages. Medications were given in an
empty stomach or two hrs after a meal. The guardians
were advised to cool patients by tepid sponging if axillary
temperature was ≥ 38.5°C, and paracetamol antipyretic, if
deemed necessary.
Study outcomes
The primary outcome measured for efficacy was cure rates
(the proportion of cases of true treatment success judged
by two negative blood smears on two consecutive occa-
sions without recrudescence parasitaemia) on day 1, 2, 3,
7, 14, and 28. Recrudescence was defined as reappearance
of peripheral parasitaemia after two or more consecutive
negative blood smears. The secondary measures were, par-
asite clearance time (PCT) defined as time taken from the
first dose of the medication to the first of two successive
negative blood smears; fever clearance times (FCTA &
FCTB), FCTA defined as time taken for the temperature to
fall for the first time below 37.5°C from first dose of the
medication; FCTB defined as time taken to become and
remain afebrile during the period of the study; and pro-
portion of patients who had gametocytes post-treatment.
Assessment of adverse events
Interactive approach was used for monitoring adverse
events. A clinician or a nurse recorded any event occurring
in the trial patients during hospital sat and during follow-
up. The patients were asked how they felt, if they had
experienced any new "feeling" after start of treatment.
Each patient was approached systematically for the pres-
ence or if they had experienced any anorexia, nausea,
vomiting, abdominal pain, headache, dizziness, or any
other events. Laboratory evaluation consisted of blood
glucose level, liver function tests, renal function tests, and
standard haematological indices at enrollment and at day
3, 7, 14, 21, and 28.
The results of the clinical and laboratory assessment were
considered adverse events if they were new or increased in
severity with respective to the baseline data. Adverse
events were defined as any symptoms or signs that were
not present on admission into the study and that were
developed after the start of treatment. All adverse events,
including those related to malaria were recorded and
compared among treatment groups.
Data management and analysis
The arithmetic mean and standard deviation (mean ± sd)
were calculated for each patient's parasitaemia. Mean par-
asitaemia values were converted to percentage, baseline
parasitaemia being 100%. Using Excel database and SPSS
software the percentages of mean parasitaemia were plot-
ted against time to assess the response pattern. Student's t-
test was used in the study for statistical significance and P
values less than 0.05 were considered to be statistically
significant. Analysis of treatment outcomes was per-
formed on the intention-to-treat basis.
Results
One hundred and thirty (n = 130) patients were recruited
into the study with positive blood smears for malaria par-
asites between June 2005 and July 2006. Thirty (n = 30)
patients were excluded for the following reasons: 10
patients had P. vivax, five patients excluded for violation
of the randomization order by one physician, one patient
had a history of psychiatric illness, one patient had renal
impairment, one patient was found be pregnant, two
patients absconded after admission before treatment
commenced. One hundred (n = 100) patients fulfilled the
criteria for final analysis; fifty-one (n = 51) patients in
ANQ group and forty-nine (n = 49) in the CQ+SP group.
Adherence to the protocol was generally good: around
94% (n = 94/100) completed follow-up; 6% (n = 6)
patients, two (n = 2) patients failed follow-up investiga-
tion on day 21 in ANQ group and four (n = 4) failed fol-
low-up investigations on 28 in the CQ+SP group.
Clinical and laboratory findings
The baseline characteristics were similar in both treatment
groups (Table 1). The patients presented with varied
symptoms suggestive of malaria including fever. These
symptoms disappeared within seven days post-treatment
in both treatment groups. None of the patients developed
severe or suffered any complications of malaria during the
course of the study. Laboratory data (Table 2) did not
show much difference between the two treatments. Pre-
treatment anaemia (Hb <10.0 g/dl) however, was
observed in 10 subjects (4/51 in ANQ and 6/49 in
CQ+SP), which improved upon treatment except in two
patients (one in each treatment group).Malaria Journal 2009, 8:196 http://www.malariajournal.com/content/8/1/196
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Fever clearance
Only 76 patients of 100 patients were evaluated for FCT;
remaining 24 patients had a temperature <37.5°C on
admission. However, within 24 hrs, 50% of the afebrile
patients in each group developed fever (≥37.5°C). The
general profile of temperature resolution in both treat-
ment groups is shown in Figure 2. The mean FCTA was
13.6 ± 9.6 hr in ANQ group versus 17.2 ± 9.9 hr in CQ+SP
(p > 0.05). The mean FCTB was 19.8 ± 12.7 hr in ANQ
group versus 31.7 ± 21.5 hr in CQ+SP group (p > 0.05).
Parasitological responses
The cure rates for ANQ on day 1, 2, 3, 7, 14, and 28 were
47%, 86%, 92%, 94%, 94% and 94%, respectively. Recru-
descence account for 6% (n = 3/51) and the recrudescence
parasitaemia cleared in all on day 21. For CQ+SP treated
group, the cure rates were 24%, 67%, 82%, 82%, 84% and
88%, respectively. Recrudescence accounted for 10% (n =
5/49) and the recrudescence parasitaemia cleared in all on
day 28. One patient (1/49; 2%) in CQ+SP group
remained parasitaemic throughout the study period. Fig-
ure 3 shows cumulative data of proportion (%) of patients
cleared of parasitaemia with time.
The parasite clearance profile for the first 72 hrs is shown
in Figure 4. The ANQ treatment was associated with rapid
reduction in parasites density within the initial 24 hr of
treatment. Unfortunately, similar response was not
observed with CQ+SP treatment. A rise in post-treatment
parasite density was observed at 16 hr after the start of
CQ+SP treatment. The reason for this phenomenon is
unknown but has been observed previously [24,25]. The
median parasite clearance time (PCT) for CQ+SP was 40
hrs (range: 16–72 hr) versus 24 hrs (range: 16–72 hr) for
ANQ.
Gametocyte carriers
Pre-treatment gametocytaemia was observed in 6 patients
(n = 3/51 in ANQ group; n = 3/49 in CQ+SP group). After
the start of the two treatments, 12% (n = 6/51) of the
patients in ANQ treated group developed gametocytes
versus 41% (n = 20/49) in CQ+SP group (p < 0.05). The
post-treatment gametocyte density was not evaluated as
this was not part of the study design.
Adverse Events Reported
Both treatment regimens were well tolerated with no seri-
ous adverse events being reported or detected. Post-treat-
ment emergent symptoms that worth noting were
transient deafness (5%, n = 5/100; 4 in ANQ group; one
in CQ+SP group), itchiness (3%, n = 3/100; one in ANQ
group, two in CQ+SP group), skin rash (2% n = 2/100;
one for each treatment group), and dark urine (1%, n = 1/
100, ANQ group only). The rate of vomiting after initiat-
ing treatment was low (one in the ANQ group, two in the
CQ+SP group) and did not differ greatly between the two
treatment groups. Several patients reported treatment
emergent symptoms such as anorexia, nausea, dizziness,
abdominal pain and headache within 24-hrs of admis-
sion. However, it was difficult to discern which of the
symptoms was malaria related and which were due to
drug treatment. One of the patients developed psychosis
~5 hours after oral administration of ANQ. The patient
had low plasma glucose (2.0 mmol/L; normal range: 3.0
– 5.0 mmol/L), which was corrected with dextrose saline.
The patient underwent psychiatric assessment (by a psy-
chiatrist) and organic causes were excluded. The patient's
condition during post-treatment follow-up was unevent-
ful. Hypoglycaemia rather than ANQ medication could
have been responsible for the psychosis.
Table 1: The pre-treatment clinical, parasitological, and demographic data of trial patients allocated ANQ and CQ+SP treatments
Pre-treatment Treatment Groups
Total number recruited: 130 ANQ CQ + SP
Numbers analyzed 51 49
Male/female 27/24 25/24
Age: median (range) 27.5 (14–60) 23.0 (14–60)
Weight (Kg): median (range) 60 (43.3–98) 56.6 (42–79)
Axillary temperature (°C) 38.2 ± 1.2 38.2 ± 1.3
Mean parasitaemia* ± sd 22228.1 ± 34567.2 19761.9 ± 36888.5
* Arithmetic meanMalaria Journal 2009, 8:196 http://www.malariajournal.com/content/8/1/196
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Discussion
Both treatments in this study cleared parasitaemia ade-
quately and reliably. However, ANQ had the more rapid
anti-malarial action, resulting in almost 50% of the trial
patients being cleared of parasites in the first 24 hours.
Moreover, ANQ treatment significantly suppressed game-
tocytogenesis than the CQ+SP treatment. What makes this
ACT unique is the claim that it is effective when adminis-
tered as a single dose, whereas other ACTs require multi-
ple dosing [26,27]. The results of this study support this
claim and further affirm the highly potent anti-malarial
and anti-gametocytocidal properties of artemisinin-based
combinations [15,28].
Table 2: Laboratory monitoring of biological events of ANQ and CQ+SP treatments




ANQ 4.9 ± 0.9 5.5 ± 1.5 4.8 ± 0.8 4.5 ± 0.8 4.5 ± 0.5 5.0 ± 1.6




ANQ 43.2 ± 16.4 43.7 ± 22.6 41.6 ± 32.1 35.7 ± 17.9 31.0 ± 10.4 33.4 ± 10.2
CQ+SP 44.2 ± 16.4 43.2 ± 16.4 42.2 ± 32.1 35.2 ± 17.9 31.0 ± 10.4 35.4 ± 10.2
**ALT
Units/L
ANQ 44.1 ± 20.9 47.9 ± 24.9 53.0 ± 49.2 57.3 ± 33.7 36.4 ± 14.8 36.3 ± 21.4
CQ+SP 46.1 ± 20.9 47.9 ± 24.9 54.0 ± 49.2 57.3 ± 34.0 36.4 ± 14.9 35.3 ± 21.4
Bilirubin
μm/L
ANQ 19.4 ± 14.3 12.1 ± 8.8 10.7 ± 5.0 8.3 ± 1.5 8.8 ± 1.3 8.8 ± 1.9
CQ+SP 18.4 ± 14.3 12.1 ± 8.8 10.6 ± 5.0 8.3 ± 1.5 8.0 ± 1.3 8.8 ± 2.0
Alkaline phosphatase
Units/L
ANQ 75.9 ± 18.6 81.8 ± 24.7 87.5 ± 27.5 91.3 ± 29.5 80.5 ± 24.3 95.1 ± 38.1
CQ+SP 76.4 ± 20.2 83.4 ± 23.1 86.1 ± 25.2 91.8 ± 28.4 77.6 ± 21.5 84.0 ± 39.0
#GGT
Units/L
ANQ 39.5 ± 22.7 40.3 ± 24.8 34.7 ± 22.3 29.5 ± 13.5 16.8 ± 11.9 22.5 ± 7.4




ANQ 92.7 ± 19.4 91.8 ± 14.2 91.9 ± 18.1 87.9 ± 13.7 85.9 ± 10.9 79.3 ± 17.5




ANQ 10.8 ± 2.3 10.6 ± 1.8 10.4 ± 1.2 10.7 ± 1.0 11.1 ± 1.7 11.6 ± 1.4
CQ+SP 11.0 ± 2.3 10.7 ± 1.9 10.5 ± 1.3 11.0 ± 0.9 11.1 ± 1.6 11.6 ± 1.5
WBC
×109/L
ANQ 5.2 ± 2.4 5.4 ± 1.7 5.5 ± 1.7 6.5 ± 2.5 6.6 ± 1.6 6.1 ± 1.7




ANQ 134.9 ± 5.6 138.2 ± 3.4 135.6 ± 7.6 137.2 ± 2.6 136.5 ± 3.1 139.6 ± 5.4
CQ+SP 135.9 ± 5.5 138.3 ± 3.3 136.1 ± 7.1 137.2 ± 2.4 136.4 ± 2.9 140.0 ± 5.5
Potassium
mm/L
ANQ 3.8 ± 0.7 4.1 ± 1.1 4.2 ± 0.8 4.1 ± 0.7 3.9 ± 0.3 4.0 ± 0.7
CQ+SP 3.8 ± 0.7 4.1 ± 0.7 4.2 ± 0.7 4.0 ± 0.7 4.0 ± 0.7 4.1 ± 1.0
*AST = Aspartate aminotransferase ** ALT = Alanine aminotransferase #GGT = Gamma-glutamyltransferaseMalaria Journal 2009, 8:196 http://www.malariajournal.com/content/8/1/196
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The ANQ combination possesses benefits of both short-
acting artemisinin, and long-acting naphthoquine com-
bined into one tablet. The administration of 8 tablets in a
single dose seems an optimal dosage for the trialed popu-
lation in treating uncomplicated falciparum malaria
infections. The dosage is safe and effective in clearing the
blood parasitaemia. Rapid reduction in blood parasitae-
mia by ANQ, without post-treatment surge in parasitae-
mia, is critical for preventing potential complications or
progression to severe and complicated malaria. However,
whether rapid clearance of parasites by ANQ makes ANQ
a more effective drug combination than CQ+SP is to be
ascertained with further studies. Interestingly, CQ+SP
combination still remain relatively effective at dosage
given (30 mg/kg over three days), despite reports of seem-
ingly moderate to high levels of multi-drug resistance in
the study areas [4-6,21]. However, increased CQ+SP post-
treatment gametocytogenesis observed in this study and
also in other studies [29-31] is a public health concern.
Gametocytes involved in "post-treatment transmission"
are more likely to carry and spread drug-resistant genetic
alleles [32]. The ACTs including ANQ combination ther-
apy provide better anti-gametocyte activities; a potential
public health benefit that could further be explored.
Recent studies show that ACTs that lack either 4-amino-
quinolines or SP in combination therapies provided bet-
ter anti-gametocytocidal activity than those combinations
that included 4-aminoquinolines or SP [33].
One of the key elements in any drug development and
evaluation is the issue of safety of the population for
which the drug is intended. Data from this study indicate
that the use of ANQ combination is relatively safe, both
from the clinical and laboratory perspectives. However,
the quinine-like transient deafness reported by several
patients who received ANQ combination requires further
investigation. Although the sample size in this study is
insufficient, larger studies are needed to define the safety
and efficacy in different populations including children
and pregnant women and in different ethnic settings. This
ACT is uniquely novel in that it can be administered less
frequently (as a single one day dose or twice a day dose)
and yet produces almost equivalent cure rates to more fre-
quently administered drug regimens such as CQ+SP com-
bination in this study or artemether-lumefantrine
combination in other studies [34]. Hence, the ANQ com-
bination therapy may be considered where compliance or
adherence to treatment is a serious issue.
In conclusion, although both combinations assessed in
this study provided relatively equivalent therapeutic
responses (efficacy), tolerability, and safety profiles at day
28, the anti-malarial action of ANQ was more rapid than
The response of the patients' axillary body temperatures (°C  = degree Celsius) after the start of the two treatments  (ANQ versus CQ+SP) Figure 2
The response of the patients' axillary body tempera-
tures (°C = degree Celsius) after the start of the two 
treatments (ANQ versus CQ+SP).
The cumulative data of proportion (%) of patients cleared of  parasitaemia with time Figure 3
The cumulative data of proportion (%) of patients 
cleared of parasitaemia with time.
The clearance of blood parasitaemia in the first seventy-two  hours (72 hrs) after the start of the two treatments (ANQ  versus CQ+SP) Figure 4
The clearance of blood parasitaemia in the first sev-
enty-two hours (72 hrs) after the start of the two 
treatments (ANQ versus CQ+SP).Malaria Journal 2009, 8:196 http://www.malariajournal.com/content/8/1/196
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CQ+SP. The ANQ combination is a potential new genera-
tion ACT, which deserves further clinical evaluation.
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